NCT01486914View on ClinicalTrials.gov

Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

January 19, 2003

Primary Completion Date

February 24, 2003

Study Completion Date

February 24, 2003

Conditions

DiabetesHealthy

Interventions

DRUG

insulin aspart

Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits

Trial Locations (1)

M15 6SH

Novo Nordisk Investigational Site, Manchester

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY